Redwire Corporation Secures $25 Million NASA Contract for Biotechnology Support on ISS

Reuters
08/28
Redwire Corporation Secures $25 Million NASA Contract for Biotechnology Support on ISS

Redwire Corporation has been awarded a NASA single award, indefinite-delivery/indefinite-quantity (IDIQ) contract with a ceiling of $25 million over a five-year period. This contract enables Redwire to fulfill future task orders for biotechnology facilities, on-orbit operations support, mission integration, and related services aboard the International Space Station (ISS). Recently, a $2.5 million task order was issued to Redwire under NASA's In Space Production Applications (InSPA) program to aid in drug development investigations using Redwire's PIL-BOX technology. As a global leader in microgravity research and development technologies, Redwire is set to manage and facilitate experiments and support on-orbit operations for NASA-funded research. The company's biotechnology facilities play a crucial role in NASA's ISS research strategy, expanding on-orbit capabilities in fields such as drug development, cancer research, and tissue engineering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redwire Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250828913799) on August 28, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10